188 related articles for article (PubMed ID: 29502008)
1. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after
Spetz J; Rudqvist N; Langen B; Parris TZ; Dalmo J; Schüler E; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2018 May; 60():11-18. PubMed ID: 29502008
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional effects of
Spetz J; Langen B; Rudqvist NP; Parris TZ; Shubbar E; Dalmo J; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
EJNMMI Res; 2019 Mar; 9(1):28. PubMed ID: 30895393
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
5. Priming increases the anti-tumor effect and therapeutic window of
Dalmo J; Spetz J; Montelius M; Langen B; Arvidsson Y; Johansson H; Parris TZ; Helou K; Wängberg B; Nilsson O; Ljungberg M; Forssell-Aronsson E
EJNMMI Res; 2017 Dec; 7(1):6. PubMed ID: 28097640
[TBL] [Abstract][Full Text] [Related]
6. Recombinant α
Andersson CK; Shubbar E; Schüler E; Åkerström B; Gram M; Forssell-Aronsson EB
J Nucl Med; 2019 Nov; 60(11):1600-1604. PubMed ID: 30926650
[TBL] [Abstract][Full Text] [Related]
7. Neuroblastoma xenograft models demonstrate the therapeutic potential of
Romiani A; Spetz J; Shubbar E; Lind DE; Hallberg B; Palmer RH; Forssell-Aronsson E
BMC Cancer; 2021 Aug; 21(1):950. PubMed ID: 34433438
[TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated Treatment with
Elvborn M; Shubbar E; Forssell-Aronsson E
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008397
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice.
Bernhardt P; Oddstig J; Kölby L; Nilsson O; Ahlman H; Forssell-Aronsson E
Cancer Biother Radiopharm; 2007 Oct; 22(5):644-53. PubMed ID: 17979567
[TBL] [Abstract][Full Text] [Related]
10. Co-administration with A1M does not influence apoptotic response of
Rassol N; Andersson C; Pettersson D; Al-Awar A; Shubbar E; Kovács A; Åkerström B; Gram M; Helou K; Forssell-Aronsson E
Sci Rep; 2023 Apr; 13(1):6417. PubMed ID: 37076494
[TBL] [Abstract][Full Text] [Related]
11. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
15. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice.
Schüler E; Rudqvist N; Parris TZ; Langen B; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2014 Mar; 41(3):238-47. PubMed ID: 24434014
[TBL] [Abstract][Full Text] [Related]
17. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Bushnell DL; Bodeker KL
Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
[TBL] [Abstract][Full Text] [Related]
18. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol.
Olmstead C; Cruz K; Stodilka R; Zabel P; Wolfson R
Nucl Med Commun; 2015 Feb; 36(2):129-34. PubMed ID: 25356620
[TBL] [Abstract][Full Text] [Related]
19. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
